Opening the book…
Current good manufacturing practice, or CGMP, refers to requirements
intended to support consistent manufacturing quality for regulated drug products. Quality depends on suitable processes, facilities, equipment, materials, training, and records. Testing the finished product cannot fully compensate for uncontrolled production. The specific requirements depend on the product and development stage.
Cell products present particular challenges because the cells are living and can change during culture. An increase in cell number may be accompanied by changes in phenotype or function. Freezing, shipping, thawing, and delays before use can also affect the preparation. A process needs controls that address the attributes important for the intended use.
Identity establishes that the product is what it is intended to be. Purity concerns the desired material and unwanted components. Potency measures biological activity relevant to the product's intended effect. A high viable cell count does not demonstrate all three. Potency testing is product-specific and may require more than one assay to assess relevant activity.
Safety-related testing may address microbial contamination, endotoxin, or other product-specific risks. Its interpretation depends on the sampling plan, assay controls, sensitivity, and acceptance criteria. A final negative result is one part of the quality system rather than evidence that every risk is absent.
A product specification defines the required tests and acceptance criteria used to judge suitability. Lot release is the documented decision that a particular lot meets the applicable conditions for its intended use. FDA guidance describes release testing in relation to safety, identity, purity, and potency, along with suitable analytical methods and acceptance criteria.
|
Attribute or record |
Question it addresses |
Evidence example |
|
Identity |
Is this the intended material? |
Product-specific characterization |
|
Purity |
What unwanted material is present? |
Tests for relevant residual components |
|
Potency |
Does it have relevant biological activity? |
An assay tied to intended function |
|
Safety-related testing |
Are specified risks acceptably controlled? |
Suitable contamination and other risk tests |
|
Traceability |
Can the source and handling be followed? |
Linked source production and transfer records |
The criteria in a clinical manufacturing program are supported by product development and the applicable framework. A textbook exercise should not invent a universal viable cell threshold or endotoxin limit for every product. Even two products using the same cell type can differ in route of administration, composition, activity, and risk.
Chain of identity maintains the link between the material and its intended source or recipient. Chain of custody documents who controlled or handled the material and when. In an autologous process, these records help keep a patient's collected cells connected to the product intended for that patient. A technically successful process with a broken identity link can still be unsuitable for use.
Worked example: acceptable test values with an unresolved identity
A preparation meets its recorded viability and potency criteria. However, the transfer record contains a sample identifier that does not match the final container. A staff member suggests releasing the material because its test values are acceptable.
The test values do not resolve which source the container represents. Keep the material in the appropriate controlled status, preserve the records, and investigate the discrepancy through the quality process. Release requires resolution according to the program's criteria and authorized review, not a guess based on appearance.
Comparability assesses whether a manufacturing change has an acceptable effect on product quality. Changing a medium, vessel, or freezing method can change more than yield. Stability evidence also supports the interval and conditions under which a product remains suitable. FDA's development guidance discusses these issues as part of cell and gene therapy development.
Attribution: "Cell Product CGMP Why Testing Isn't Enough" AI-generated using NotebookLM. Modified by Emalee Mackenzie, Irvine Valley College. Licensed under CC BY-NC-SA
This page titled 16.7: Manufacturing Quality and Product Release was last modified on Wed, 21 Oct 2026 01:35:46 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.